Table 2.
Relapse characteristics.
| Relapse Characteristics | All | Molecular Relapse |
Hematologic Relapse |
|---|---|---|---|
| No. | 151 | 59 | 92 |
| Time to relapse, median (range), months | 4.8 (0.9–211) |
5.1 (0.9–211) |
4.3 (0.9–110) |
|
WBC, median
(range), ×109/L |
3.7 (0.3–48.6) |
3.8 (0.3–20.2) |
3.5 (0.6–48.6) |
|
PB Blasts, median
(range), % |
0 (0–71) |
0 (0) |
0 (0–71) |
|
BM Blasts, median
(range), % |
7 (0–92) |
2.5 (0–5) |
21.5 (1–92) |
|
Median Hb, median
(range), g/dL |
11.4 (7.2–17) |
11.8 (7.4–15.7) |
11.3 (7.2–17) |
|
Platelets, median
(range), ×109/L |
95 (6–800) |
128 (18–800) |
60 (6–205) |
|
PB chimerism, median
(range), % |
86.3 (0–100) |
97.8 (20.6–100) |
77.1 (0–100) |
|
BM chimerism, median
(range), % |
87.3 (1.2–100) |
96.7 (8.3–100) |
66.7 (1.2–99.7) |
|
Extramedullary relapse isolated with systemic relapse |
0 5 |
0 1 |
0 4 |
|
aGvHD * before relapse yes no ≥grade 3 cGvHD † before relapse yes no severe |
50 (33%) 101 (67%) 12 (8%) 14 (9%) 137 (91%) 0 |
17 42 2 4 55 0 |
33 59 10 10 82 0 |
|
Immunosuppression at Aza Start yes no missing |
61 (40%) 64 (42%) 26 (17%) |
30 26 3 |
31 38 23 |
|
aGvHD * after treatment with Aza +/− DLI yes no ≥grade 3 cGvHD † after treatment with Aza +/− DLI yes no severe |
63 (42%) 88 (58%) 16 (11%) 40 (26%) 111 (74%) 5 (3%) |
25 34 9 20 39 3 |
38 54 7 20 72 2 |
Note: * modified according to Glucksberg et al. [23]; † according to Filipovich et al. [24]; aGvHD, acute graft-versus-host disease; Aza, Azacitidine; BM, bone marrow; cGvHD, chronic graft-versus-host disease; d, days; DLI, donor lymphocyte infusion; Hb, hemoglobin; PB, peripheral blood; WBC, white blood cells.